2022
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases 2022, 76: e342-e349. PMID: 35653428, PMCID: PMC9214014, DOI: 10.1093/cid/ciac443.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 vaccination statusVaccination statusHazard ratioCOVID-19Severe acute respiratory syndrome coronavirus 2High-risk patients trialModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Adjusted hazard ratioHigh-risk patientsTreatment of mildCox hazard regressionSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerEligible patientsOlder patientsRisk patientsHazards regressionCoronavirus 2Cardiovascular diseaseTime-dependent variables
2021
The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction
Bahouth F, Elias A, Ghersin I, Khoury E, Bar O, Sholy H, Khoury J, Azzam Z. The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction. ESC Heart Failure 2021, 9: 585-594. PMID: 34821080, PMCID: PMC8788061, DOI: 10.1002/ehf2.13710.Peer-Reviewed Original ResearchConceptsReduced ejection fractionHeart rateHeart failureHazard ratioEjection fractionPrognostic valueTarget doseMortality rateChronic stable heart failureBeta-blocker dosageHeart failure settingAdjusted hazard ratioStable heart failureDay mortality rateSingle-center studyRetrospective observational studyYear mortality rateElevated heart rateLower heart rateHR 70Acute decompensationCause mortalityLaboratory variablesYear mortalityCox regression